Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Ambion Announce Co-Marketing Deal

NEW YORK, Aug 10 - Agilent Technologies and Ambion have agreed to co-market several of their products, including the Agilent 2100 bioanalyzer, Agilent RNA LabChip kits, and Ambion's RNA-related reagents. 

The companies said that by combining forces, they would be able to offer customers a range of products for improved RNA analysis.

"A key advantage of the LabChip technology for RNA analysis includes the ability to access the quality of an RNA sample," Bill Buffington, general manager of Agilent's life sciences division, said in a statement released Thursday. "Customers can use Ambion's RNase Zap to protect RNA from RNase degradation.”

Together Agilent of Palo Alto, Calif., and Ambion of Austin, Texas, will co-market the products and conduct market research. They did not disclose the financial terms of the deal.

Agilent’s RNA LabChip kits are developed and manufactured by Caliper Technology, Agilent's partner for its lab-on-a-chip business.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.